翰宇药业(300199) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 247,332,327.41, representing a year-on-year increase of 133.19%[9] - Net profit attributable to shareholders was CNY 8,806,324.76, an increase of 105.62% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 243,119.83, up 100.14% year-on-year[9] - Basic earnings per share for the reporting period were CNY 0.01, an increase of 105.88% year-on-year[9] - The company reported a net profit of 8,781,987.94 yuan for the current period, compared to a net loss of 156,720,538.93 yuan in the previous period[62] - Operating revenue for the current period was 239,689,844.28 yuan, an increase from 99,713,222.90 yuan in the previous period, representing a growth of approximately 140%[67] - Net profit for the current period was ¥55,870,023.74, a significant recovery from a net loss of ¥80,048,492.42 in the previous period[77] - The company’s total comprehensive income for the current period is ¥295,346,121.34, compared to a loss of ¥95,084,839.39 in the previous period[87] Cash Flow - The net cash flow from operating activities was CNY -25,630,315.01, a decrease of 87.68% compared to the same period last year[9] - The net cash flow from operating activities improved by 123.04% to RMB 34,855,618.27, mainly due to reduced cash outflows from operating activities[24] - Operating cash flow for the current period is ¥34,855,618.27, a significant improvement from a net cash outflow of ¥151,301,147.17 in the previous period[90] - Total cash inflow from operating activities is ¥731,773,408.25, while cash outflow is ¥696,917,789.98, resulting in a net cash flow from operating activities of ¥34,855,618.27[90] - Cash and cash equivalents at the end of the period amount to ¥567,342,501.41, down from ¥1,078,829,719.91 in the previous period[96] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,722,867,627.09, a decrease of 0.04% compared to the end of the previous year[9] - The total current assets decreased from 1.89 billion RMB at the end of 2019 to 1.76 billion RMB, reflecting a decline of approximately 6.8%[40] - The total non-current assets increased from 2.83 billion RMB at the end of 2019 to 2.96 billion RMB, an increase of about 4.5%[42] - The total liabilities decreased to ¥2,170,164,038.72 from ¥2,189,809,258.09, indicating a reduction of approximately 0.9%[56] - Total liabilities amounted to CNY 2,491,661,693.71, with non-current liabilities at CNY 1,355,941,290.71[109] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,565[13] - The largest shareholder, Zeng Shaoguai, holds 21.81% of the shares, totaling 199,964,249 shares[13] - The equity attributable to shareholders of the parent company increased to ¥2,274,914,803.20 from ¥2,228,206,315.81, marking a growth of about 2.1%[49] Expenses and Investments - The company experienced a 196.42% increase in operating expenses, primarily due to increased donations related to the COVID-19 pandemic[24] - Research and development expenses increased to 17,856,344.64 yuan from 15,566,912.76 yuan, reflecting a rise of about 14.7%[67] - The company plans to invest up to RMB 20 million in a new healthcare investment partnership, with a total fund size not exceeding RMB 100 million[27] Government Support - The company received government subsidies amounting to CNY 25,628,161.06 during the reporting period[12] Market Outlook - The company is in the process of a non-public stock issuance to enhance its capital strength and market competitiveness in the peptide pharmaceutical industry[27] - The company plans to continue focusing on market expansion and new product development to drive future growth[79]